durvalumab đŸ¶ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
human origin 5234 1428935-60-7

Description:

MoleculeDescription

Synonyms:

  • durvalumab
  • MEDI4736
  • MEDI 4736
  • imfinzi
  • durvalumab (genetical recombination)
Durvalumab is a human immunoglobulin G1 kappa (IgG1Îș) monoclonal antibody that blocks the interaction of PD-L1 with PD-1 and CD80 (B7.1). Blockade of PD-L1/PD-1 and PD-L1/CD80 interactions releases the inhibition of immune responses, without inducing antibody dependent cellmediated cytotoxicity (ADCC). PD-L1 blockade with durvalumab led to increased T-cell activation in vitro and decreased tumor size in co-engrafted human tumor and immune cell xenograft mouse models.
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

DoseUnitRoute
53.60 mg P

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

DateAgencyCompanyOrphan
Sept. 21, 2018 EMA ASTRAZENECA AB
July 2, 2018 PMDA AstraZeneca KK
May 1, 2017 FDA ASTRAZENECA UK LTD

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Malignant neoplasm progression 745.12 31.13 310 8888 106560 90512689
Radiation pneumonitis 655.67 31.13 120 9078 1738 90617511
Death 455.07 31.13 372 8826 456179 90163070
Pneumonitis 439.46 31.13 166 9032 44004 90575245
Cholangitis 188.02 31.13 56 9142 7126 90612123
Metastases to central nervous system 181.72 31.13 68 9130 17474 90601775
Biliary tract infection 181.63 31.13 36 9162 808 90618441
Neutrophil count decreased 159.56 31.13 96 9102 71436 90547813
Immune-mediated enterocolitis 150.62 31.13 43 9155 4714 90614535
Hypothyroidism 149.64 31.13 83 9115 53044 90566205
Colitis 146.07 31.13 90 9108 69852 90549397
Myocarditis 137.47 31.13 52 9146 13754 90605495
Myelosuppression 127.50 31.13 75 9123 53516 90565733
Immune-mediated hepatitis 108.62 31.13 30 9168 2914 90616335
Liver abscess 103.52 31.13 30 9168 3466 90615783
Febrile neutropenia 97.44 31.13 99 9099 158250 90460999
Immune-mediated lung disease 97.11 31.13 25 9173 1855 90617394
Cholangitis infective 95.03 31.13 19 9179 446 90618803
Immune-mediated myocarditis 90.30 31.13 22 9176 1303 90617946
Thyroiditis 89.30 31.13 27 9171 3610 90615639
Interstitial lung disease 85.43 31.13 67 9131 76338 90542911
Platelet count decreased 83.09 31.13 85 9113 136884 90482365
Anaemia 81.85 31.13 136 9062 352666 90266583
Pyrexia 81.16 31.13 195 9003 660290 89958959
Immune-mediated hepatic disorder 74.21 31.13 20 9178 1772 90617477
Embolism 74.20 31.13 30 9168 9451 90609798
Tumour hyperprogression 73.07 31.13 13 9185 158 90619091
Pemphigoid 72.15 31.13 29 9169 8997 90610252
Hepatic function abnormal 70.70 31.13 49 9149 46239 90573010
Urinary tract obstruction 69.71 31.13 20 9178 2229 90617020
Cytokine release syndrome 68.73 31.13 40 9158 27933 90591316
Bile duct stenosis 65.41 31.13 18 9180 1724 90617525
Hyperthyroidism 63.85 31.13 33 9165 18277 90600972
Bacterial abdominal infection 62.64 31.13 9 9189 22 90619227
Myasthenia gravis 61.81 31.13 24 9174 6801 90612448
Pleural effusion 61.62 31.13 66 9132 111925 90507324
Nephritis 58.69 31.13 19 9179 3176 90616073
Drug-induced liver injury 58.30 31.13 58 9140 90260 90528989
Metastatic malignant melanoma 57.39 31.13 16 9182 1608 90617641
Metastases to liver 57.37 31.13 36 9162 28771 90590478
Neoplasm progression 56.26 31.13 42 9156 44444 90574805
Small intestinal obstruction 53.85 31.13 31 9167 21203 90598046
Haematotoxicity 53.76 31.13 26 9172 12509 90606740
Immune-mediated hypothyroidism 53.46 31.13 15 9183 1543 90617706
Metastases to lung 53.40 31.13 28 9170 15963 90603286
Arterial intramural haematoma 53.30 31.13 10 9188 166 90619083
Pulmonary toxicity 52.74 31.13 25 9173 11506 90607743
Immune-mediated adverse reaction 52.10 31.13 13 9185 850 90618399
Adrenal insufficiency 51.22 31.13 34 9164 29887 90589362
Immune-mediated myositis 51.08 31.13 16 9182 2405 90616844
Type 1 diabetes mellitus 51.07 31.13 19 9179 4793 90614456
Liver carcinoma ruptured 49.59 31.13 8 9190 51 90619198
Metastases to bone 48.60 31.13 31 9167 25474 90593775
Thrombophlebitis migrans 48.60 31.13 10 9188 272 90618977
Neuropathy peripheral 47.76 31.13 64 9134 136906 90482343
Polyneuropathy 45.78 31.13 27 9171 19314 90599935
Disease progression 43.99 31.13 66 9132 156549 90462700
Neutropenia 42.08 31.13 79 9119 224825 90394424
Eastern Cooperative Oncology Group performance status worsened 41.68 31.13 13 9185 1926 90617323
Pain 41.50 31.13 25 9173 996316 89622933
Sepsis 41.16 31.13 69 9129 179745 90439504
Bacillus infection 41.11 31.13 11 9187 948 90618301
Tubulointerstitial nephritis 39.09 31.13 27 9171 25316 90593933
Headache 38.28 31.13 20 9178 862726 89756523
Skin toxicity 38.22 31.13 17 9181 6762 90612487
Enterocolitis 36.84 31.13 19 9179 10471 90608778
Non-small cell lung cancer recurrent 36.83 31.13 7 9191 125 90619124
Drug ineffective 34.32 31.13 55 9143 1384243 89235006
Encephalitis 32.97 31.13 18 9180 11116 90608133
Immune-mediated cholangitis 31.36 31.13 7 9191 282 90618967

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Radiation pneumonitis 2127.39 22.65 431 16380 2502 42602022
Malignant neoplasm progression 1066.51 22.65 611 16200 107789 42496735
Pneumonitis 733.70 22.65 348 16463 41370 42563154
Death 547.21 22.65 788 16023 470397 42134127
Interstitial lung disease 456.28 22.65 318 16493 78144 42526380
Immune-mediated enterocolitis 417.05 22.65 134 16677 5543 42598981
Metastases to central nervous system 348.87 22.65 137 16674 10218 42594306
Neutrophil count decreased 326.83 22.65 239 16572 63176 42541348
Immune-mediated hepatic disorder 263.65 22.65 78 16733 2436 42602088
Myelosuppression 218.49 22.65 157 16654 40304 42564220
Myocarditis 212.73 22.65 117 16694 18821 42585703
Cholangitis 201.95 22.65 94 16717 10633 42593891
Immune-mediated hepatitis 185.87 22.65 66 16745 3708 42600816
Colitis 179.68 22.65 148 16663 46424 42558100
Eastern Cooperative Oncology Group performance status worsened 173.69 22.65 49 16762 1287 42603237
Immune-mediated myocarditis 171.64 22.65 54 16757 2080 42602444
Pulmonary toxicity 160.29 22.65 75 16736 8580 42595944
Hypothyroidism 136.49 22.65 108 16703 31976 42572548
Adrenal insufficiency 134.31 22.65 87 16724 18837 42585687
Non-small cell lung cancer recurrent 129.83 22.65 23 16788 53 42604471
Liver disorder 126.41 22.65 113 16698 39531 42564993
Cytokine release syndrome 120.84 22.65 116 16695 44411 42560113
Immune-mediated lung disease 120.60 22.65 47 16764 3426 42601098
Myositis 112.06 22.65 71 16740 14795 42589729
Hepatic function abnormal 111.85 22.65 119 16692 51448 42553076
Liver carcinoma ruptured 94.44 22.65 22 16789 260 42604264
Immune-mediated dermatitis 93.51 22.65 30 16781 1231 42603293
Drug interaction 88.54 22.65 4 16807 266995 42337529
Biliary tract infection 88.46 22.65 26 16785 792 42603732
Tumour hyperprogression 87.18 22.65 19 16792 162 42604362
Lung disorder 82.37 22.65 98 16713 47825 42556699
Febrile neutropenia 81.83 22.65 207 16604 185496 42419028
Hypopituitarism 80.35 22.65 33 16778 2758 42601766
Hyperthyroidism 73.56 22.65 54 16757 14287 42590237
Immune thrombocytopenia 73.32 22.65 49 16762 11167 42593357
Metastases to adrenals 72.72 22.65 24 16787 1078 42603446
Metastases to bone 72.01 22.65 54 16757 14755 42589769
Oesophagitis 68.42 22.65 53 16758 15194 42589330
Adrenocorticotropic hormone deficiency 67.60 22.65 24 16787 1346 42603178
Platelet count decreased 65.76 22.65 159 16652 138422 42466102
Drug-induced liver injury 63.67 22.65 77 16734 38196 42566328
Hypophysitis 61.70 22.65 28 16783 2983 42601541
Enterocolitis 61.61 22.65 42 16769 9887 42594637
Enterocolitis infectious 58.97 22.65 24 16787 1959 42602565
Fulminant type 1 diabetes mellitus 56.35 22.65 21 16790 1353 42603171
Immune-mediated adrenal insuficiency 56.28 22.65 18 16793 731 42603793
Drug ineffective 53.70 22.65 105 16706 630092 41974432
Metastases to liver 52.91 22.65 47 16764 16279 42588245
Encephalitis autoimmune 52.68 22.65 20 16791 1357 42603167
Haematotoxicity 51.07 22.65 39 16772 10946 42593578
Metastases to lymph nodes 48.59 22.65 30 16781 5968 42598556
Gastrointestinal toxicity 45.79 22.65 25 16786 3954 42600570
Thyroiditis 44.79 22.65 23 16788 3213 42601311
Immune-mediated hypophysitis 44.04 22.65 13 16798 402 42604122
Myasthenia gravis 43.65 22.65 42 16769 16095 42588429
Thrombocytopenia 42.68 22.65 168 16643 190111 42414413
Pneumothorax 41.84 22.65 49 16762 23494 42581030
Type 1 diabetes mellitus 40.82 22.65 26 16785 5461 42599063
Immune-mediated adverse reaction 40.15 22.65 15 16796 973 42603551
Metastases to lung 39.25 22.65 34 16777 11390 42593134
Fall 39.05 22.65 22 16789 234498 42370026
Pleural effusion 38.28 22.65 104 16707 97062 42507462
Pulmonary radiation injury 38.22 22.65 8 16803 55 42604469
Pain in extremity 37.52 22.65 7 16804 150597 42453927
Diffuse uveal melanocytic proliferation 35.95 22.65 6 16805 8 42604516
Headache 35.02 22.65 26 16785 239343 42365181
Adrenal disorder 33.84 22.65 14 16797 1191 42603333
Immune-mediated pancreatitis 33.55 22.65 10 16801 320 42604204
Immune-mediated myositis 33.36 22.65 20 16791 3773 42600751
Immune-mediated hypothyroidism 33.09 22.65 14 16797 1260 42603264
Anxiety 32.98 22.65 4 16807 118556 42485968
Immune-mediated nephritis 32.97 22.65 12 16799 723 42603801
Immune-mediated cholangitis 32.83 22.65 11 16800 518 42604006
Pain 32.82 22.65 29 16782 244819 42359705
Lichenoid keratosis 32.62 22.65 20 16791 3930 42600594
Haemoptysis 32.23 22.65 62 16749 46105 42558419
Somnolence 32.21 22.65 8 16803 141097 42463427
Blood thyroid stimulating hormone decreased 30.68 22.65 16 16795 2307 42602217
Immune-mediated encephalitis 30.66 22.65 11 16800 636 42603888
Pneumonia bacterial 30.13 22.65 34 16777 15658 42588866
Pneumonia 29.84 22.65 275 16536 421874 42182650
Pyrexia 29.53 22.65 260 16551 393782 42210742
Paraneoplastic neurological syndrome 29.16 22.65 7 16804 95 42604429
Tumour pseudoprogression 28.82 22.65 12 16799 1038 42603486
Thyroxine free abnormal 28.38 22.65 5 16806 11 42604513
Protein induced by vitamin K absence or antagonist II increased 27.87 22.65 6 16805 48 42604476
Disease progression 27.59 22.65 121 16690 143535 42460989
Pancreatic enzymes increased 27.31 22.65 11 16800 874 42603650
Insomnia 26.41 22.65 7 16804 118246 42486278
Skin disorder 26.40 22.65 33 16778 16911 42587613
Dizziness 26.26 22.65 36 16775 249218 42355306
Hepatic infection 25.25 22.65 10 16801 760 42603764
Liver function test increased 25.06 22.65 35 16776 19963 42584561
Lymphoma transformation 25.04 22.65 9 16802 523 42604001
Hypothalamo-pituitary disorder 25.00 22.65 11 16800 1089 42603435
Oropharyngeal oedema 24.37 22.65 6 16805 91 42604433
Tumour marker increased 24.36 22.65 10 16801 834 42603690
Cholangitis acute 24.29 22.65 11 16800 1166 42603358
Thrombophlebitis migrans 24.18 22.65 8 16803 362 42604162
Autoimmune hepatitis 23.97 22.65 19 16792 5626 42598898
Overdose 23.95 22.65 6 16805 105258 42499266
Liver abscess 23.88 22.65 18 16793 4952 42599572
Muscle spasms 23.69 22.65 3 16808 86041 42518483
Seizure 23.62 22.65 9 16802 120552 42483972
Metastases to pleura 23.54 22.65 9 16802 622 42603902
Bradycardia 23.49 22.65 3 16808 85481 42519043
Diabetic ketoacidosis 23.47 22.65 36 16775 22331 42582193
Condition aggravated 23.34 22.65 42 16769 260712 42343812
Hepatitis 23.29 22.65 40 16771 27260 42577264
Nasopharyngitis 22.95 22.65 3 16808 83993 42520531

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Radiation pneumonitis 2851.29 24.42 533 22483 4003 110562280
Malignant neoplasm progression 1413.91 24.42 699 22317 173868 110392415
Pneumonitis 892.34 24.42 395 22621 76136 110490147
Interstitial lung disease 613.92 24.42 374 22642 138960 110427323
Death 592.45 24.42 725 22291 698144 109868139
Immune-mediated enterocolitis 547.51 24.42 163 22853 10022 110556261
Neutrophil count decreased 515.61 24.42 318 22698 120623 110445660
Cholangitis 406.79 24.42 146 22870 16189 110550094
Metastases to central nervous system 404.52 24.42 159 22857 22658 110543625
Immune-mediated hepatic disorder 383.43 24.42 103 22913 4347 110561936
Myelosuppression 324.85 24.42 217 22799 94123 110472160
Myocarditis 311.17 24.42 143 22873 29912 110536371
Immune-mediated hepatitis 282.32 24.42 89 22927 6622 110559661
Colitis 269.96 24.42 200 22816 102123 110464160
Hypothyroidism 268.66 24.42 175 22841 72724 110493559
Biliary tract infection 263.04 24.42 63 22953 1661 110564622
Immune-mediated myocarditis 250.45 24.42 70 22946 3428 110562855
Cytokine release syndrome 221.17 24.42 153 22863 70153 110496130
Hepatic function abnormal 214.35 24.42 165 22851 89130 110477153
Eastern Cooperative Oncology Group performance status worsened 206.12 24.42 58 22958 2911 110563372
Febrile neutropenia 202.16 24.42 287 22729 316480 110249803
Pulmonary toxicity 191.71 24.42 87 22929 17659 110548624
Adrenal insufficiency 189.35 24.42 115 22901 42275 110524008
Platelet count decreased 185.59 24.42 234 22782 230209 110336074
Immune-mediated lung disease 184.93 24.42 61 22955 5242 110561041
Non-small cell lung cancer recurrent 172.56 24.42 31 22985 179 110566104
Liver carcinoma ruptured 134.39 24.42 27 22989 303 110565980
Tumour hyperprogression 131.60 24.42 27 22989 339 110565944
Immune-mediated dermatitis 124.53 24.42 37 22979 2253 110564030
Hyperthyroidism 122.03 24.42 76 22940 29185 110537098
Thyroiditis 120.64 24.42 47 22969 6526 110559757
Drug-induced liver injury 117.98 24.42 135 22881 119932 110446351
Metastases to bone 114.72 24.42 75 22941 31297 110534986
Myositis 112.84 24.42 74 22942 31042 110535241
Immune thrombocytopenia 110.76 24.42 65 22951 22429 110543854
Liver disorder 107.39 24.42 140 22876 142103 110424180
Pyrexia 107.28 24.42 419 22597 897846 109668437
Pain 107.10 24.42 33 22983 954922 109611361
Pleural effusion 102.96 24.42 154 22862 177555 110388728
Hypopituitarism 100.89 24.42 37 22979 4353 110561930
Adrenocorticotropic hormone deficiency 100.40 24.42 31 22985 2151 110564132
Myasthenia gravis 100.27 24.42 60 22956 21451 110544832
Liver abscess 99.88 24.42 43 22973 7696 110558587
Oesophagitis 91.43 24.42 63 22953 28652 110537631
Hypophysitis 89.86 24.42 36 22980 5379 110560904
Metastases to adrenals 87.60 24.42 26 22990 1577 110564706
Headache 86.24 24.42 38 22978 882339 109683944
Drug interaction 84.13 24.42 5 23011 500178 110066105
Thrombocytopenia 83.92 24.42 208 22808 348677 110217606
Metastases to liver 81.82 24.42 64 22952 35322 110530961
Fulminant type 1 diabetes mellitus 81.66 24.42 27 22989 2336 110563947
Anaemia 81.04 24.42 274 22742 546812 110019471
Immune-mediated hypothyroidism 80.30 24.42 28 22988 2847 110563436
Cholangitis infective 79.77 24.42 21 22995 818 110565465
Metastases to lung 79.14 24.42 53 22963 23010 110543273
Immune-mediated myositis 78.62 24.42 34 22982 6152 110560131
Encephalitis autoimmune 78.36 24.42 29 22987 3499 110562784
Haematotoxicity 76.10 24.42 50 22966 21032 110545251
Bile duct stenosis 74.50 24.42 26 22990 2650 110563633
Enterocolitis 73.45 24.42 47 22969 18902 110547381
Immune-mediated adverse reaction 73.38 24.42 23 22993 1677 110564606
Joint swelling 72.76 24.42 5 23011 442840 110123443
Pemphigoid 69.34 24.42 46 22970 19661 110546622
Immune-mediated cholangitis 69.30 24.42 19 22997 865 110565418
Immune-mediated adrenal insuficiency 68.23 24.42 22 22994 1758 110564525
Drug hypersensitivity 66.92 24.42 8 23008 454082 110112201
Pain in extremity 66.13 24.42 11 23005 487107 110079176
Nasopharyngitis 66.12 24.42 4 23012 394357 110171926
Abdominal discomfort 66.02 24.42 4 23012 393854 110172429
Type 1 diabetes mellitus 63.41 24.42 33 22983 9014 110557269
Thrombophlebitis migrans 62.37 24.42 17 22999 757 110565526
Embolism 62.14 24.42 40 22976 16249 110550034
Radiation interaction 61.91 24.42 11 23005 59 110566224
Pneumothorax 61.13 24.42 54 22962 35231 110531052
Lichenoid keratosis 59.03 24.42 28 22988 6274 110560009
Sepsis 58.47 24.42 175 22841 327171 110239112
Gastrointestinal toxicity 56.95 24.42 33 22983 11115 110555168
Peripheral swelling 55.10 24.42 9 23007 404025 110162258
Drug ineffective 55.08 24.42 150 22866 1520390 109045893
Dizziness 53.95 24.42 40 22976 698153 109868130
Pulmonary radiation injury 53.75 24.42 10 23006 72 110566211
Metastases to lymph nodes 52.67 24.42 35 22981 14997 110551286
Weight increased 51.64 24.42 12 23004 419632 110146651
Drug intolerance 51.28 24.42 11 23005 406501 110159782
Bacterial abdominal infection 51.18 24.42 9 23007 45 110566238
Anxiety 51.02 24.42 6 23010 345072 110221211
Immune-mediated nephritis 50.40 24.42 16 23000 1216 110565067
Encephalitis 50.00 24.42 37 22979 18802 110547481
Hepatic infection 49.57 24.42 16 23000 1283 110565000
Depression 48.22 24.42 5 23011 317330 110248953
Arthropathy 47.93 24.42 3 23013 287519 110278764
Pneumonia 47.88 24.42 329 22687 876385 109689898
Diabetic ketoacidosis 47.68 24.42 51 22965 42007 110524276
Immune-mediated pancreatitis 45.10 24.42 13 23003 711 110565572
Cytopenia 44.19 24.42 42 22974 30074 110536209
Immune-mediated encephalitis 42.74 24.42 14 23002 1176 110565107
Organising pneumonia 42.42 24.42 30 22986 14213 110552070
Product use issue 42.36 24.42 7 23009 311688 110254595
Arterial intramural haematoma 42.33 24.42 10 23006 248 110566035
Immune-mediated hypophysitis 41.21 24.42 13 23003 968 110565315
Pneumonia bacterial 41.18 24.42 38 22978 26223 110540060
Respiratory failure 40.21 24.42 117 22899 215215 110351068
Haemoptysis 40.08 24.42 61 22955 71293 110494990
Nephritis 39.12 24.42 21 22995 6105 110560178
Tumour pseudoprogression 38.54 24.42 14 23002 1602 110564681
Superior vena cava syndrome 37.22 24.42 13 23003 1328 110564955
Immune-mediated arthritis 37.14 24.42 11 23005 662 110565621
Neuropathy peripheral 36.98 24.42 101 22915 179176 110387107
Protein induced by vitamin K absence or antagonist II increased 36.98 24.42 7 23009 56 110566227
Cholangitis acute 36.24 24.42 14 23002 1899 110564384
Neutropenia 36.08 24.42 164 22852 374456 110191827
Immune-mediated thyroiditis 35.79 24.42 12 23004 1084 110565199
Paraneoplastic neurological syndrome 34.95 24.42 8 23008 172 110566111
Autoimmune hepatitis 34.70 24.42 27 22989 14777 110551506
Fall 34.55 24.42 45 22971 603437 109962846
Tubulointerstitial nephritis 34.22 24.42 49 22967 54235 110512048
Wheezing 34.08 24.42 6 23010 255224 110311059
Abdominal pain upper 34.06 24.42 15 23001 349096 110217187
Lymphoma transformation 33.89 24.42 10 23006 594 110565689
Cholangitis sclerosing 33.81 24.42 16 23000 3566 110562717
Urinary tract obstruction 33.77 24.42 18 22998 5159 110561124
Lung disorder 32.81 24.42 97 22919 179950 110386333
Hypersensitivity 32.67 24.42 22 22994 403976 110162307
Pericardial effusion 32.25 24.42 49 22967 57168 110509115
Diffuse uveal melanocytic proliferation 31.90 24.42 5 23011 10 110566273
Immune-mediated renal disorder 31.80 24.42 10 23006 737 110565546
Malignant pleural effusion 31.78 24.42 16 23000 4077 110562206
Polyneuropathy 31.42 24.42 36 22980 31976 110534307
Enterocolitis infectious 31.34 24.42 15 23001 3429 110562854
Small intestinal obstruction 31.23 24.42 36 22980 32177 110534106
Carcinoembryonic antigen increased 30.98 24.42 14 23002 2810 110563473
Arthralgia 30.33 24.42 74 22942 779558 109786725
Overdose 30.14 24.42 6 23010 233788 110332495
Cerebral infarction 30.08 24.42 45 22971 51793 110514490
Radiation oesophagitis 30.03 24.42 10 23006 884 110565399
Oesophagomediastinal fistula 29.76 24.42 5 23011 18 110566265
Hepatic failure 29.45 24.42 52 22964 68687 110497596
Erythema 29.26 24.42 12 23004 291435 110274848
Condition aggravated 29.17 24.42 69 22947 734767 109831516
Renal colic 29.07 24.42 14 23002 3244 110563039
Pemphigus 28.74 24.42 5 23011 214565 110351718
Somnolence 28.67 24.42 13 23003 297436 110268847
Insomnia 28.67 24.42 20 22996 360570 110205713
Metastases to pleura 28.40 24.42 12 23004 2051 110564232
Metastasis 28.36 24.42 19 22997 8248 110558035
Therapeutic product effect incomplete 28.32 24.42 6 23010 223799 110342484
Diarrhoea 28.17 24.42 361 22655 1139144 109427139
Lower respiratory tract infection 27.88 24.42 8 23008 243098 110323185
Bacillus infection 27.72 24.42 11 23005 1603 110564680
Skin disorder 27.44 24.42 39 22977 42874 110523409
Lipase increased 27.32 24.42 26 22990 18646 110547637
Helicobacter infection 27.27 24.42 3 23013 181874 110384409
Autoimmune nephritis 27.03 24.42 9 23007 795 110565488
Blood pressure increased 26.99 24.42 10 23006 258363 110307920
Intentional product use issue 26.92 24.42 9 23007 247897 110318386
Autoimmune hypothyroidism 26.67 24.42 8 23008 503 110565780
Dyspepsia 26.59 24.42 4 23012 190961 110375322
Adrenal disorder 26.50 24.42 12 23004 2420 110563863
Duodenal ulcer perforation 26.47 24.42 3 23013 177697 110388586
Hepatic encephalopathy 26.43 24.42 31 22985 28225 110538058
White blood cell count decreased 26.37 24.42 106 22910 229284 110336999
Asthma 25.63 24.42 10 23006 250281 110316002
Memory impairment 25.50 24.42 5 23011 196939 110369344
Psoriatic arthropathy 25.46 24.42 5 23011 196756 110369527
Tumour haemorrhage 25.40 24.42 15 23001 5230 110561053
Neoplasm progression 25.30 24.42 47 22969 64548 110501735
Musculoskeletal pain 25.10 24.42 4 23012 183019 110383264
Stress cardiomyopathy 25.03 24.42 23 22993 15783 110550500
Enteritis 24.89 24.42 25 22991 19131 110547152
Hypothalamo-pituitary disorder 24.70 24.42 12 23004 2834 110563449
Feeling abnormal 24.67 24.42 4 23012 180707 110385576
Tumour rupture 24.66 24.42 8 23008 652 110565631

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L01FF03 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors
MeSH PA D000074322 Antineoplastic Agents, Immunological
MeSH PA D000970 Antineoplastic Agents
FDA CS M0001357 Antibodies, Monoclonal
FDA MoA N0000193336 Programmed Death Ligand-1-directed Antibody Interactions
FDA MoA N0000193337 Programmed Death Ligand-1 Antagonists
FDA EPC N0000193338 Programmed Death Ligand-1 Blocker
CHEBI has role CHEBI:35610 antineoplastic agent
CHEBI has role CHEBI:64951 anti-HBV agent
CHEBI has role CHEBI:233423 antifibrotic agent

Related Drugs by ATC class:

L01FF PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors 11 drugs
atezolizumabavelumabcemiplimabdostarlimabnivolumabpembrolizumabretifanlimabserplulimabsugemalimabtislelizumabtoripalimab

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Transitional cell carcinoma indication 27090000 DOID:2671
Liver cell carcinoma indication 109841003 DOID:684
Small cell carcinoma of lung indication 254632001 DOID:5409
Non-small cell lung cancer indication 254637007 DOID:3908
Extensive stage primary small cell carcinoma of lung indication
Metastatic carcinoma to biliary tract indication




đŸ¶ Veterinary Drug Use

None

đŸ¶ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Programmed cell death 1 ligand 1 CD molecules ANTIBODY BINDING UNKNOWN DRUG LABEL

External reference:

IDSource
28X28X9OKV UNII
4036653 VANDF
C4055109 UMLSCUI
CHEBI:755270 CHEBI
CHEMBL3301587 ChEMBL_ID
DB11714 DRUGBANK_ID
D10808 KEGG_DRUG
10010 INN_ID
C000613593 MESH_SUPPLEMENTAL_RECORD_UI
7985 IUPHAR_LIGAND_ID
735230005 SNOMEDCT_US
763588004 SNOMEDCT_US
256648 MMSL
32681 MMSL
d08576 MMSL
017200 NDDF
1919503 RXNORM

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
IMFINZI HUMAN PRESCRIPTION DRUG LABEL 1 0310-4500 INJECTION, SOLUTION 120 mg INTRAVENOUS BLA 24 sections
IMFINZI HUMAN PRESCRIPTION DRUG LABEL 1 0310-4611 INJECTION, SOLUTION 500 mg INTRAVENOUS BLA 24 sections